The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study

Jamy D. Ard,Ian J. Neeland,Amy E. Rothberg,Robert J. Chilton,Daniel Luis,Sarah S. Cohen,Odd Erik Johansen,Daniel de Luis
DOI: https://doi.org/10.1111/dom.15392
2023-12-12
Diabetes Obesity and Metabolism
Abstract:Aim The effects of weight loss with a partial or total meal replacement programme (MRP) on atherosclerotic cardiovascular disease (ASCVD) risk factors are not fully understood, in particular in people at higher CV risk. In the 52‐week randomized controlled OPTIWIN study in men and women with obesity, meal replacement programme (total for first 26 weeks, partial for the ensuing 26 weeks) with OPTIFAST (OP) resulted in significantly greater weight loss compared with a low‐calorie food‐based (FB) dietary plan, both as part of a comprehensive lifestyle intervention [OP (n = 135)/FB (n = 138) week 26: −12.4%/−6.0%, p
endocrinology & metabolism
What problem does this paper attempt to address?